Solara Active Pharma Sciences Limited announced that the United States Food and Drug Administration (USFDA or agency) vide its letter on June 22, 2020, has informed the Company about classifying the manufacturing site at Cuddalore, Tamil Nadu as "Official Action Indicated"(OAI). This outcome is based on the USFDA's inspection at the site between March 2 to March 7, 2020. The company announced that it is disappointed with this classification, and is strongly committed to collaborating with the USFDA to satisfactorily resolve the issues raised by the agency in the form 483 issued to the Company. The reclassification of the Cuddalore site will not impact the business continuity for fiscal 2021. The company continues to maintain its fiscal 2021 guidance both on the revenues and EBITDA.